All In Biotech

Drug Trial Radar · NCT03322540

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Dec 15, 2017

Primary completion

Jan 10, 2019

Study completion Nov 9, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).

Conditions

  • Lung Cancer

Interventions

  • PembrolizumabDrug

    Pembrolizumab administered intravenously every 3 weeks.

  • EpacadostatDrug

    Epacadostat administered orally twice daily.

  • PlaceboDrug

    Matching placebo administered orally twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus PlaceboTime frame: Up to approximately 6 months

Locations

101 sites in 18 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Florida Cancer Specialists (South Region)

    Fort Myers, Florida

  • Florida Cancer Specialists (North Region)

    St. Petersburg, Florida

  • Southeastern Regional Medical Center, Inc.

    Newnan, Georgia

  • Anne Arundel Health System Research Institute

    Annapolis, Maryland

  • Weinberg Cancer Institute at Franklin Square

    Baltimore, Maryland

  • Maryland Oncology Hematology, P.A.

    Rockville, Maryland

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Minnesota Oncology Hematology, PA

    Coon Rapids, Minnesota

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Tennessee Oncology, PLLC/The Sarah Cannon Research Institute

    Chattanooga, Tennessee

  • Tennessee Oncology, PLLC/The Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology-South Austin

    Austin, Texas

  • Austin Health-Austin Hospital

    Heidelberg, Victoria, Australia

  • St John of God Murdoch Medical Clinic

    Murdoch, Western Australia, Australia

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Moncton Hospital - Horizon Health Network

    Moncton, New Brunswick, Canada

  • William Osler Health System

    Brampton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario at Kingston General Hospital

    Kingston, Ontario, Canada

  • Sault Area Hospital

    Sault Ste. Marie, Ontario, Canada

  • Rigshospitalet

    Copenhagen, Denmark

  • Regionshospitalet Herning

    Herning, Denmark

  • Odense Universitetshospital

    Odense, Denmark

  • SA Tartu Ulikooli Kliinikum

    Tartu, Estonia

  • St Vincents University Hospital

    Dublin, Ireland

  • Galway University Hospital

    Galway, Connacht, Ireland

  • Soroka Medical Center

    Beersheba, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Meir Medical Center

    Kfar Saba, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • IRCCS A.O.U. San Martino - IST

    Genova, Italy

  • Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Niigata Cancer Center Hospital

    Niigata, Japan

  • Okayama University Hospital

    Okayama, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.